Disentangling the relationship between cholesterol, aggression, and impulsivity in severe mental disorders

Gabriela Hjell1,2 | Lynn Mørch-Johnsen1,2 | René Holst2,3 | Natalia Tesli1 | Christina Bell1 | Synve Hoffart Lunding1 | Linn Rødevand1 | Maren Caroline Frogner Werner1 | Ingrid Melle1 | Ole Andreas Andreassen1 | Trine Vik Lagerberg1 | Nils Eiel Steen1 | Unn Kristin Haukvik1,4,5

Abstract

Objective: Low total cholesterol has been linked with adverse mental symptoms such as aggression and impulsivity in severe mental disorders (SMDs). This putative association may affect the clinician's decision making about cholesterol lowering in this patient group. Here, we investigated the associations between cholesterol levels, aggression, and impulsivity in a large representative sample of in- and outpatients with SMD.

Methods: Patients with schizophrenia- or bipolar spectrum disorders (N = 1001) underwent thorough clinical characterization and blood sampling (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol). Aggression was characterized by the Positive and Negative Syndrome Scale Excited Component. Impulsivity was measured with the Barratt Impulsiveness Scale in a subsample of patients (N = 288). We used a multinomial logistic regression model to analyze the association between cholesterol and aggression and a multiple linear regression model to analyze the association between cholesterol and impulsivity, while controlling for confounders.

Results: We found no significant associations between cholesterol levels and aggression or impulsivity. There were no significant interactions between cholesterol and diagnostic group or inpatient versus outpatient status. Controlling for medication use, body mass index, alcohol or illicit substance use did not affect the results.

Conclusion: In this large sample of patients with schizophrenia- and bipolar spectrum disorders, we found no associations between cholesterol levels and aggression or impulsivity. This has clinical implications as patients with SMD are at increased CVD risk and currently undertreated with statins.

KEYWORDS

aggression, bipolar disorder, cardiovascular disease, cholesterol, schizophrenia
**1 | SIGNIFICANT OUTCOMES**

- A large representative sample of patients with schizophrenia- and bipolar disorder were at increased risk of adverse outcomes including aggressive behavior, suicide, and premature mortality (Fazel et al., 2015; Fazel, Wolf, Palm, & Lichtenstein, 2014; Fleishman, Werbeloff, Yoffe, Davidson, & Weiser, 2014; Hayes, Miles, Walters, King, & Osborn, 2015; Walter et al., 2019). Cardiovascular diseases (CVDs) are among the leading causes of death in patients with SMD (Olsson, Gerhard, Huang, Crystal, & Stroup, 2015; Swaraj et al., 2019; Tanskanen, Tiitonen, & Taipale, 2018). Cholesterol lowering has strong protective effect on CVD mortality (Benjamin et al., 2018; Boekholdt et al., 2014), and the current cholesterol management guidelines (Grundy et al., 2019; Piepoli et al., 2016) advise initiation of statin therapy based on calculations of CVD risk. As a step toward personalized cholesterol management, the excessive CVD risk in SMDs (Laursen et al., 2013) has been taken into account in the development of CVD risk assessment tools (Hippisley-Cox, Coupland, & Brindle, 2017; Osborn et al., 2015). Low total cholesterol (TC) has, however, been linked with adverse mental symptoms such as aggression and impulsivity in SMDs (Tomson-Johanson & Harro, 2018). As such, the recommendations regarding cholesterol management may risk potentiating aggressive dispositions. Although most patients with SMD will never be aggressive, aggression and violent acts challenge everyday psychiatric clinical practice. Establishing the association between cholesterol and aggression and impulsivity in patients with SMD is therefore of high clinical relevance for personalized CVD prevention.

- Psychological effects of cholesterol lowering have been robustly addressed in the general population (Collins et al., 2016). Even though an early meta-analysis of primary CVD prevention randomized controlled trials (RCTs) linked decrease in TC to an increase in violent deaths caused by accident, homicide, and suicide (Muldoon, Manuck, & Matthews, 1990), subsequent research did not show adverse psychological effects of cholesterol lowering in the general public (Golomb et al., 2015; Muldoon, Manuck, Mendelsohn, Kaplan, & Belle, 2001). An explicit or implicit exclusion of individuals with SMD in these RCTs may limit our knowledge about psychological effects of cholesterol lowering in SMD patient group (Rothwell, 2005). Moreover, individuals with SMD might be particularly susceptible to potential adverse psychological effects of low TC. Genome-wide association studies implicate a role of cholesterol metabolism in SMDs (Andreason et al., 2013). Cholesterol has been shown to interact with serotonin (Kaplan et al., 1994; Veveara et al., 2016), which is central in the pathophysiology of mental disorders (Lucki, 1998) and aggression (Coccaro, Fanning, Phan, & Lee, 2015; Klasen et al., 2019). Despite the protective role of the blood–brain barrier against direct effects of circulating levels of cholesterol on the brain, indirect mechanisms mediated by cholesterol metabolites have been demonstrated (Olsson et al., 2017).

Cholesterol and adverse mental symptoms have been investigated over the past three decades in a number of smaller-to-medium scaled studies in psychiatric settings (Apter et al., 1999; De Berardis et al., 2013; Eriksen, Bjorkly, Lockertsen, Faerden, & Roaldset, 2017; Huang & Wu, 2000; Kavoor, Mitra, Kumar, Sisodia, & Jain, 2017; Mufti, Balon, & Arfken, 1998; Roaldset, Bakken, & Bjorkly, 2011; Steinert, Woelfle, & Gebhardt, 1999; Suneson et al., 2019; Troisi, 2011; Wu et al., 2016), often showing inverse associations between TC and degree of aggression, impulsivity, or suicidality. Moreover, low TC has been associated with more frequent acts of aggression in forensic psychiatric populations (Hillbrand, Spitz, & Foster, 1995; Paavola, Repo-Tiihonen, & Tiitonen, 2002). A meta-analysis of the relationship between cholesterol and suicidality has shown inverse association between TC and suicidality (Wu et al., 2016). Several studies have shown inverse associations between TC and aggression (Hillbrand et al., 1995; Mufti et al., 1998; Paavola et al., 2002; Roaldset et al., 2011; Suneson et al., 2019) or impulsivity (Kavoor et al., 2017; Troisi, 2011), whereas other studies have reported no significant associations between TC and aggression (Apter et al., 1999; Eriksen et al., 2017; Huang & Wu, 2000; Kavoor et al., 2017; Steinert et al., 1999) or impulsivity (Apter et al., 1999). Findings among those studies that have investigated high-density lipoprotein cholesterol (HDL-C) (Eriksen et al., 2017; Kavoor et al., 2017; Paavola et al., 2002; Suneson et al., 2019; Troisi, 2011) vary from positive (Paavola et al., 2002), to inverse (Eriksen et al., 2017), to nonsignificant (Troisi, 2011; Kavoor et al., 2017; Suneson et al., 2019) associations with aggression. Additionally, inverse associations between low-density lipoprotein cholesterol (LDL-C) and aggression (Paavola et al., 2002; Suneson et al., 2019) or impulsivity (Kavoor et al., 2017) have been reported. Taken together, the body of evidence appears to be split into suggestions of lipid profile with low cholesterol (TC, LDL-C) and suggestions of no distinct lipid profile pattern related to aggression. These substantial inconsistencies in findings and a focus restricted to inpatient settings call for an investigation of the association between cholesterol and aggression in a large representative sample of patients with SMD.

The aim of the present study was to determine the associations between cholesterol levels and aggression and impulsivity by investigating a large sample of in- and outpatients with schizophrenia or bipolar disorder. We hypothesized that cholesterol levels...
(TC, LDL-C) would be negatively associated with aggression and impulsivity in patients with SMD. For completeness, we aimed to provide insight into how HDL-C contributes to the hypothesized TC associations. Hence, we postulated that HDL-C also would be negatively associated with aggression and impulsivity in patients with SMD.

4 | MATERIAL AND METHODS

4.1 | Participants

The present study is part of the Thematically Organized Psychosis (TOP) study, which recruits patients with SMD from psychiatric in- and outpatient clinics of the major hospitals in Oslo, Norway (Rodevand et al., 2019). The main inclusion criterion was a diagnosis within the schizophrenia- or bipolar spectrum. Further inclusion criteria were age between 18 and 65 years, ability to give informed consent, and Norwegian language skills sufficient for valid assessments. Exclusion criteria comprised marked cognitive deficit (IQ scores below 70), neurological disorder, and history of severe head trauma. The study participants were recruited between the years 2002 and 2017. Patients (N = 1,001) were classified in the following diagnostic groups according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) (American Psychiatric Association, 1994): schizophrenia spectrum disorders (N = 601), including schizophrenia (N = 360), schizophreniform disorder (N = 31), schizoaffective disorder (N = 96), delusional disorder (N = 36), and psychotic disorder not otherwise specified (NOS) (N = 78); bipolar spectrum disorders (N = 400), including bipolar I disorder (N = 229), bipolar II disorder (N = 112), bipolar disorder NOS (N = 21), and major depressive disorder with psychotic features (N = 38).

4.2 | Clinical measures

All participants were thoroughly assessed by trained psychologists and physicians. The diagnostic evaluation was based on the Structured Clinical Interview for DSM-IV axis I disorders (SCID-I) (First, Spitzer, Gibbon, & Williams, 1995), including a review of medical records. The inter-rater diagnostic agreement has been estimated to a satisfying level of 82% with overall \( \kappa = 0.77 \) (95% CI: 0.60–0.94) (Rodevand et al., 2019). General psychiatric symptom load was evaluated using the Global Assessment of Functioning Split Version (GAF) (Pedersen, Hagtvet, & Karterud, 2007). Affective symptoms were assessed with the Young Mania Rating Scale (YMRS) (Young, Biggs, Ziegler, & Meyer, 1978) and the Calgary Depression Scale for Schizophrenia (CDSS) (Addington, Addington, & Schissel, 1990). The Positive and Negative Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987) was used to rate current psychotic symptoms, achieving inter-rater reliability of intraclass correlation coefficient at 0.82 (Rodevand et al., 2019). The PANSS consists of 30 items, each scored from 1 (no symptoms) to 7 (severe symptoms).

A measure of aggression among patients was obtained using the PANSS Excited Component (PANSS-EC) (Montoya et al., 2011), which is a part of the Five Factor PANSS Model (White, Harvey, Opler, & Lindenmayer, 1997). The PANSS-EC was calculated as a sum of the following items: P4-excitement, P7-hostility, G4-tension, G8-uncooperativeness, and G14-poor impulse control (Lindenmayer et al., 2004). The PANSS-EC is commonly used as a primary outcome measure in RCTs targeted at agitation and aggressive behavior in emergency psychiatric settings (Citrome, 2007; Zeller et al., 2017). Due to the distribution of PANSS-EC scores in our sample, PANSS-EC was grouped into the following categories reflecting the level of aggression: PANSS-EC = 5 represents a group with no aggression symptoms (NAS), PANSS-EC ranging from 6 to 10 represents a group with minimal level of aggression symptoms (MLAS), and PANSS-EC > 10 represents a group with higher levels of aggression symptoms (HLAS). The unifactorial structure of the PANSS-EC (Montoya et al., 2011) and PANSS rating criteria (Kay et al., 1987) were used as a background for the establishment of the cutoffs. Thus, the first group NAS was defined by the absence of all PANSS-EC symptoms, the second group MLAS spanned from outer end of the normal range to suspected pathology, and PANSS-EC scores indicative of more certain and expressed pathology were categorized into the third group HLAS. The PANSS assessment was conducted within one month of the blood sampling (median 9 days, interquartile range 9 days).

Impulsivity was measured with the Barratt Impulsiveness Scale (BIS-11) (Patton, Stanford, & Barratt, 1995) questionnaire among a subgroup of patients (N = 288). The BIS-11 consists of 30 items scored on a 4-point Likert scale. Hence, the total score ranges from 30 to 120, with higher scores reflecting higher levels of impulsivity. Internal consistency of the BIS-11 total score has been repeatedly reported as acceptable (Lindstrom, Wyller, Halvorsen, Hartberg, & Lundqvist, 2017; Patton et al., 1995; Reise, Moore, Sabb, Brown, & London, 2013; Stanford et al., 2009).

The Alcohol Use Disorders Identification Test (AUDIT) (Babor et al.,) and the Drug Use Disorders Identification Test (DUDIT) (Voluse et al., 2012) questionnaires were used to evaluate alcohol and illicit substance use. Information about psychopharmacological treatment was collected from medical records and by interview. Current dose in use relative to the defined daily dose (DDD) was calculated in line with the guidelines from the World Health Organization Collaborating Center for Drug Statistics Methodology (https://www.whocc.no/atc_ddd_index/). Body mass index (BMI) (kg/m²) was calculated based on weight and height measurements.

4.3 | Serum analyses

Venous blood samples were collected in the morning after an overnight fast of at least 8 hr. Levels of TC, LDL-C, and HDL-C were measured at the Department of Medical Biochemistry, Oslo University Hospital, on routine instruments (Roche Diagnostics Cobas Integra 800, Roche Diagnostics Cobas 8000 e602/e801) using standard
methods controlled by internal and external quality control samples. Until 2012, LDL-C was calculated by the Friedewald formula (Martin et al., 2013), thereafter analyzed by an enzymatic colorimetric method.

4.4 | Ethical considerations

The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. The TOP study has approvals from the Regional Ethics Committee, the Norwegian Data Inspectorate, and the Norwegian Directorate of Health.

4.5 | Statistical analyses

Statistical analyses were performed using IBM SPSS Statistics for Windows version 25.0 software package. Normality was assessed by Kolmogorov–Smirnov tests and Q–Q plots. Differences in demographic and clinical characteristics across the aggression categories were investigated using chi-squared tests, one-way ANOVAs with post hoc t tests, or Kruskal–Wallis tests with post hoc Mann–Whitney U tests. All descriptive analyses were two-tailed, with a significance level at 0.05.

We used a multinomial logistic regression model to analyze the association between cholesterol (TC, LDL-C, HDL-C) and the three levels of aggression (NAS, MLAS, HLAS), with cholesterol levels as the independent variable, adjusting for age, sex, and diagnostic group (schizophrenia- versus bipolar spectrum disorders). Then, we repeated the analyses with additional adjustments (BMI, inpatient versus outpatient status, alcohol use (AUDIT scores), illicit substance use (DUDIT scores) and use of psychotropic medication (dose relative to DDD) including antipsychotics, antidepressants, mood stabilizers, and lithium) in a subsample with all the covariates available (N = 689). Variation inflation factors (VIFs) were used to assess multicollinearity. Interactions between cholesterol levels (TC, LDL-C, HDL-C) and diagnostic group, inpatient versus outpatient status, and sex were tested. We applied the Bonferroni method to correct for multiple testing (analyses with TC, LDL-C, and HDL-C as independent variable), with a significance level at 0.017 (0.05/3).

5 | RESULTS

5.1 | Descriptive analyses

Demographic and clinical characteristics of the sample with aggression outcome are summarized in Table 1. There were significant differences in age (p < .001), education level (p < .001), and symptom load (GAF (p < .001), PANSS total score (p < .001), CDSS (p < .001), YMRS (p < .001) between the three aggression groups, with age decreasing and symptom load increasing gradually with increasing levels of aggression. Schizophrenia spectrum disorders were significantly more frequent than bipolar spectrum disorders in the HLAS group compared to the remaining groups (p = .009). There were no significant differences in uncorrected cholesterol levels across the three groups.

Demographic and clinical characteristics of the subsample with impulsivity outcome are summarized in Table 2.

5.2 | Aggression

The raw data are presented in Figure 1. As shown in Table 3 and Table S1, there were no significant associations between TC, LDL-C, or HDL-C and aggression category when controlled for other covariates. There were no significant interactions between cholesterol levels (TC, LDL-C, HDL-C) and diagnostic group, inpatient versus outpatient status, or sex. Age was significantly negatively associated with aggression level (HLAS versus NAS (p < .001). There were no significant associations of sex, inpatient versus outpatient status, BMI, alcohol use, illicit substance use, or psychotropic medication with aggression category when controlled for other covariates. The total sample (N = 1001) and the subsample with all covariates available (N = 689) yielded the same results, with two exceptions. Firstly, there was a significant association of diagnostic group with the HLAS versus NAS status in the total sample (p = .006), as opposed to no significant association of diagnostic group in the subsample. Secondly, the subsample showed an additional negative association of age with MLAS versus NAS status (p = .011).

5.3 | Impulsivity

Scatterplots of cholesterol levels (TC, LDL-C, HDL-C) and impulsivity (BIS-11 total score) are presented in Figure 2. As shown in Table 4 and Table S2, there were no significant associations between TC, LDL-C, or HDL-C and impulsivity when controlled for other covariates. There were no significant interactions between cholesterol levels (TC, LDL-C, HDL-C) and diagnostic group, inpatient versus outpatient status or sex. Illicit substance use was significantly positively associated with impulsivity (p < .001). There were no
significant associations of sex, diagnosis, BMI, inpatient versus outpatient status, alcohol use, or use of psychotropic medication with impulsivity when controlled for other covariates. The total sample (N = 288) and the subsample with all covariates available (N = 259) yielded the same results, with exception of age being significantly negatively associated with impulsivity in the subsample (p = .016) as opposed to nonsignificant association in the total sample.

### DISCUSSION

The main finding of this study was an absence of significant associations between cholesterol levels and aggression or impulsivity in a large naturalistic sample of patients with schizophrenia- and bipolar spectrum disorders. This is to date the largest clinical study of cholesterol and aggression or impulsivity in SMDs, expanding the
### TABLE 2 Demographic and clinical characteristics of the sample with impulsivity outcome

|                          | N = 288 |
|--------------------------|---------|
| Male                     | 146 (50.7) |
| Caucasian                | 232 (80.8) |
| Schizophrenia spectrum disorder | 157 (54.5) |
| Bipolar spectrum disorder | 131 (45.5) |
| Outpatient               | 207 (72.9) |
| Currently smoking        | 145 (50.9) |
| Use of statins           | 1 (0.3) |

|                          | Mean (SD) |
|--------------------------|-----------|
| BIS–11 total score       | 68.6 (10.8) |
| GAF-S                    | 53.5 (13.6) |
| GAF-F                    | 52.7 (13.6) |
| PANSS total score        | 52.2 (13.8) |
| TC in mmol/L             | 4.88 (0.95) |
| LDL-C in mmol/L          | 3.06 (0.85) |
| HDL-C in mmol/L          | 1.43 (0.44) |

|                          | Median (IQR) |
|--------------------------|--------------|
| Age                      | 27 (13)      |
| Years of education       | 12 (3)       |
| CDSS                     | 6 (3)        |
| YMRS                     | 4 (7)        |
| AUDIT                    | 6 (3)        |
| DUDIT                    | 6 (3)        |
| Antipsychotics           | 0.75 (1.50)  |
| Lithium                  | 0 (0)        |
| Mood stabilizers         | 0 (0)        |
| Antidepressants          | 0 (0.17)     |
| BMI                      | 25.2 (6.2)   |

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; BIS-11, Barratt Impulsiveness Scale; BMI, body mass index; CDSS, Calgary Depression Scale for Schizophrenia; DUDIT, Drug Use Disorders Identification Test; GAF-F, Global Assessment of Functioning Split Version-Function; GAF-S, Global Assessment of Functioning Split Version-Symptoms; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; PANSS, Positive and Negative Syndrome Scale; PANSS-EC, Positive and Negative Syndrome Scale Excited Component; SD, standard deviation; TC, total cholesterol; YMRS: Young Mania Rating Scale.

*Information about inpatient versus outpatient status available for N = 287, about smoking status for N = 285, about GAF-F for N = 286, about PANSS total score for N = 285, about CDSS for N = 285, about YMRS for N = 234, about AUDIT for N = 283, about DUDIT for N = 286, about antipsychotics for N = 272, about lithium N = 276, about mood stabilizers N = 276, about antidepressants N = 275, and about BMI for N = 282.

*Psychotropic medications as current daily dose relative to defined daily dose.

Scope of investigations to the outpatient psychiatric population. We found no significant interactions between cholesterol levels and diagnostic group or inpatient versus outpatient status on aggression or impulsivity.

In contrast to our hypothesis, lower cholesterol levels were not associated with higher levels of aggression or impulsivity. The literature on cholesterol and aggression in psychiatric populations is conflicting. Several studies have shown inverse associations between TC and aggression (Hillbrand et al., 1995; Mufti et al., 1998; Paavola et al., 2002; Roaldset et al., 2011; Suneson et al., 2019) or impulsivity (Kavoor et al., 2017; Troisi, 2011), whereas other studies have reported no significant associations between TC and aggression (Apter et al., 1999; Eriksen et al., 2017; Huang & Wu, 2000; Kavoor et al., 2017; Steinert et al., 1999) or impulsivity (Apter et al., 1999).

Importantly, these were observational studies, and the findings may represent reverse causality with cholesterol levels reflecting the severity of distress among specific psychiatric populations. The negative findings in the current study are based on investigations among patients within a wide range of illness stages and severity, which may explain some of the discrepancy. As previously published (Gohar et al., 2019), an overlapping sample revealed no significant associations between TC and suicidal behavior. Considering the relationship between cholesterol levels and adverse mental symptoms in general, the meta-analytic investigation of the relationship between TC and suicidality showing an inverse association is of importance (Wu et al., 2016). Since this meta-analysis was based on cross-sectional designs, causality remains unelucidated. Moreover, the need of exploring confounding variables has been highlighted in this context (Bartoli et al., 2017). Our results are more in line with results from RCTs in the general population which have not indicated adverse psychological effects of cholesterol lowering (Collins et al., 2016; Golomb et al., 2015; Muldoon et al., 2001). Experimental animal studies (Haagensen et al., 2014; Kaplan, Manuck, & Shively, 1991) suggest that very high TC levels (above double the high end of the normal range) might indeed have protective effects against aggressive behavior. Interestingly, a negative association between prepubertal TC and adulthood impulsivity has been reported in healthy men (Tomson-Johanson, Kaart, kilvet, Veidebaum, & Harro, 2019).

As aggression is a highly complex phenomenon, the possibility that unmeasured confounders overshadow weak associations between cholesterol levels and aggression cannot be ruled out. However, all lines of evidence taken together, findings do not suggest clinically significant adverse effects of cholesterol lowering on aggression in adults with SMDs.

Some studies, the present study included, aimed at estimating the association between exposure (i.e., cholesterol levels) and outcome (i.e., aggression), while other studies aspired prediction of the outcome using range of available covariates including variables such as history of violence or involuntary hospitalization (Roaldset et al., 2011). As such, complexity of the literature may be partly explained by these different methodological approaches motivated by different aims (Pearl, 2000). Despite extensive methodological
heterogeneity, there are some common aspects of the previous research. Several previous studies have limited sample size (Kavoor et al., 2017; Mufti et al., 1998; Suneson et al., 2019). Many of the previous study designs involve testing for multiple cholesterol fractions (Eriksen et al., 2017; Kavoor et al., 2017; Paavola et al., 2002; Suneson et al., 2019; Troisi, 2011). However, none of these studies apply correction for multiple testing, implying a risk of false-positive results. In terms of potential confounding, most of the previous study designs controlled for demographic variables such as sex and age, whereas the current study accounted also for
TABLE 3  Multinomial logistic regression with aggression categories as dependent and TC as independent variable

|                                | B (SE)  | Wald   | p      | OR (95% CI)     |
|--------------------------------|---------|--------|--------|-----------------|
| **HLAS versus NAS, total sample (N = 1001)** |         |        |        |                 |
| TC                             | 0.00 (0.12) | 0.00   | .971   | 1.00 (0.80 to 1.26) |
| Age                            | −0.05 (0.01) | 13.37  | <.001  | 0.95 (0.93 to 0.98) |
| Gender = male                  | −0.23 (0.23) | 0.94   | .332   | 0.80 (0.51 to 1.26) |
| Diagnosis = schizophrenia spectrum disordera | 0.70 (0.25) | 7.69   | .006   | 2.01 (1.23 to 3.29) |
| **MLAS versus NAS, total sample (N = 1001)** |         |        |        |                 |
| TC                             | −0.01 (0.07) | 0.02   | .895   | 0.99 (0.86 to 1.15) |
| Age                            | −0.01 (0.01) | 3.00   | .083   | 0.99 (0.97 to 1.00) |
| Gender = male                  | 0.03 (0.15) | 0.05   | .823   | 1.03 (0.77 to 1.39) |
| Diagnosis = schizophrenia spectrum disordera | 0.11 (0.15) | 0.55   | .458   | 1.12 (0.83 to 1.51) |
| **HLAS versus NAS, subsample (N = 689)** |         |        |        |                 |
| TC                             | 0.04 (0.16) | 0.07   | .796   | 1.04 (0.77 to 1.42) |
| Age                            | −0.05 (0.02) | 9.52   | .002   | 0.95 (0.92 to 0.98) |
| Gender = male                  | −0.33 (0.30) | 1.22   | .270   | 0.72 (0.40 to 1.30) |
| Diagnosis = schizophrenia spectrum disordera | 0.51 (0.35) | 2.13   | .144   | 1.67 (0.84 to 3.33) |
| Inpatient versus outpatient status = inpatient | −0.32 (0.34) | 0.89   | .346   | 0.73 (0.37 to 1.42) |
| BMI                            | −0.02 (0.03) | 0.53   | .467   | 0.98 (0.92 to 1.04) |
| AUDIT                          | 0.03 (0.02) | 1.79   | .181   | 1.03 (0.99 to 1.08) |
| DUDIT                          | −0.00 (0.02) | 0.04   | .836   | 1.00 (0.96 to 1.04) |
| Antipsychotics                 | −0.05 (0.17) | 0.10   | .755   | 0.95 (0.68 to 1.32) |
| Antidepressants                | −0.05 (0.19) | 0.07   | .798   | 0.95 (0.66 to 1.38) |
| Mood stabilizers               | −0.15 (0.47) | 0.10   | .752   | 0.86 (0.35 to 2.15) |
| Lithium                        | −0.39 (0.53) | 0.55   | .459   | 0.68 (0.24 to 1.91) |
| **MLAS versus NAS, subsample (N = 689)** |         |        |        |                 |
| TC                             | 0.02 (0.10) | 0.03   | .859   | 1.02 (0.84 to 1.24) |
| Age                            | −0.02 (0.01) | 5.69   | .017   | 0.98 (0.96 to 1.00) |
| Gender = male                  | 0.08 (0.19) | 0.17   | .680   | 1.08 (0.75 to 1.57) |
| Diagnosis = schizophrenia spectrum disordera | 0.10 (0.22) | 0.23   | .630   | 1.11 (0.73 to 1.70) |
| Inpatient versus outpatient status = inpatient | −0.08 (0.22) | 0.12   | .730   | 0.93 (0.60 to 1.44) |
| BMI                            | −0.02 (0.02) | 1.49   | .223   | 0.98 (0.94 to 1.02) |
| AUDIT                          | −0.02 (0.02) | 0.95   | .329   | 0.99 (0.96 to 1.02) |
| DUDIT                          | −0.00 (0.02) | 0.00   | .955   | 1.00 (0.97 to 1.03) |
| Antipsychotics                 | −0.04 (0.11) | 0.14   | .711   | 0.96 (0.78 to 1.19) |
| Antidepressants                | 0.19 (0.11) | 2.99   | .084   | 1.21 (0.98 to 1.49) |
| Mood stabilizers               | 0.11 (0.25) | 0.19   | .660   | 1.12 (0.68 to 1.84) |
| Lithium                        | −0.32 (0.25) | 1.71   | .191   | 0.73 (0.45 to 1.17) |

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; CI, confidence interval; DUDIT, Drug Use Disorders Identification Test; HLAS group with higher levels of aggression symptoms; MLAS, group with minimal level of aggression symptoms; NAS, group with no aggression symptoms; OR, odds ratio; SE, standard error; TC, total cholesterol.

*aDiagnosis variable: schizophrenia spectrum disorder versus bipolar spectrum disorder.

p ≤ .017 in bold.
FIGURE 2 Scatterplot of cholesterol levels and impulsivity: (a) TC, (b) LDL-C, (c) HDL-C. Impulsivity measured by BIS-11 total score (y-axis). Cholesterol levels in mmol/l (x-axis). Abbreviations: BIS-11, Barratt Impulsiveness Scale; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

---

diagnosis, medication, BMI, and substance use. These issues are addressed in the current study by the large sample size and stringent statistical approach. Moreover, a variety of aggression outcome measures are applied in the field. Findings linking low TC with aggressive behavior are based on studies that have operationalized registrations of aggressive behavior over a longer time period (Hillbrand et al., 1995; Mufti et al., 1998; Paavola et al., 2002; Roaldset et al., 2011), whereas studies that have used registrations acquired over a shorter time period (Apter et al., 1999; Huang & Wu, 2000; Kavoor et al., 2017; Steinert et al., 1999) do not show
This link. This may suggest that trait properties of aggression implied in this link can be descriptive of antisocial personality traits rather than of acts of aggression itself. This is supported by findings from criminal settings (Virkkunen, 1979) and general population (Freedman et al., 1995). Two outcome measures with different properties were used to assess aggression-related behavior (Garcia-Forero, Gallardo-Pujol, Maydeu-Olivares, & Andres-Pueyo, 2009) in our study design. As such, aggression and impulsivity were addressed using both state (PANSS-EC) and trait (BIS-11) measures, encompassing both interviewer-rated and questionnaire-based approaches to outcome measure acquisition.

The main strengths of our study are representativeness of inpatient- and outpatient settings, thorough characterization of the sample, large sample size, and thus the opportunity of applying a stringent statistical approach. We controlled for potential confounding factors such as BMI, medication, and substance use, and we adjusted for multiple comparisons. These are methodological aspects targeting the key challenges in the field such as external validity and risk of false-positive findings.

The present study also has some noteworthy limitations. Despite adjustments for a comprehensive range of variables, residual confounding cannot be ruled out. Moreover, as a consequence of the naturalistic study design, the highest levels of aggression were scarcely represented among the study participants. Exploratory plots presented in the current study did not indicate nonlinear associations between cholesterol and aggression or impulsivity; thus, no comprehensive investigations targeted at nonlinearity (Sedgwick, Young, Das, & Kumari, 2016) were conducted.

As of relevance for CVD risk management, the median age of patients in our sample was 29 years, which is below the recommended age of 40 years for initiation of systematic CVD risk evaluation and consecutive statin therapy initiation. As such, our sample with only 16 statin users was not suitable to investigate specific associations between statin use and adverse mental symptoms. Studies from psychiatric settings linking TC and aggression have been mainly conducted among statin nonusers (Mufti et al., 1998; Paavola et al., 2002; Suneson et al., 2019). There are neither findings from SMD populations (Leppien, Mulcahy, Demler, Trigoboff, & Opler, 2018) nor robust findings from the general population (Collins et al., 2016) supporting the concept of aggression as a side effect of statin use, independent of cholesterol levels.

### 7 CONCLUSION

We found no associations between cholesterol levels and aggression or impulsivity in this representative large sample of patients.
with schizophrenia- and bipolar spectrum disorders. This has clinical implications as CVDs are among leading causes of substantially reduced life expectancy in SMDs (Laursen et al., 2013), and patients with SMD are currently undertreated with statins (Mitchell, Lord, & Malone, 2012). An undertreatment of CVD risk in patients with comorbid SMD is a complex clinical challenge contributing to high morbidity and mortality rates in SMDs, implicating health care in both psychiatry and general practice (Jones, Howard, & Thornicroft, 2008; Leucht, Burkard, Henderson, Maj, & Sartorius, 2007; Woodhead et al., 2016).

ACKNOWLEDGMENTS
The authors would like to thank the study participants for their valuable contribution, the staff members at NORMENT for the acquisition of data and Department of Medical Biochemistry at Oslo University Hospital Ulleval, Oslo, Norway, for the serum analyses. Funding: This work was supported by the Research Council of Norway (223273), the South-Eastern Norway Health Authorities. Funding: This work was supported by the Research Council of Norway (223273), the South-Eastern Norway Health Authorities (2020100), and Ostfold Hospital (AB3461).

CONFLICT OF INTEREST
Ole Andreas Andreassen has received consultancy fees from HealthLytix and speaker’s honorarium from Lundbeck. All other authors report no conflict of interest.

AUTHOR CONTRIBUTION
GH, NES, and UKH wrote the first draft, and all authors critically revised and approved the manuscript.

PEER REVIEW
The peer review history for this article is available at https://publ

DATA AVAILABILITY STATEMENT
The data are not publicly available due to privacy and ethical restrictions.

ORCID
Gabriela Hjell https://orcid.org/0000-0002-1257-6731
Linn Rødevand https://orcid.org/0000-0001-5967-6601

REFERENCES
Addington, D., Addington, J., & Schissel, B. (1990). A depression rating scale for schizophrenics. Schizophrenia Research, 3(4), 247–251. https://doi.org/10.1016/0920-9964(90)90055-5
American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders : DSM-IV (4th edn). Washington, D.C: American Psychiatric Association.
Andreassen, O. A., Djurovic, S., Thompson, W. K., Schork, A. J., Kendler, K. S., & Dale, A. M. (2013). Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. American Journal of Human Genetics, 92(2), 197–209. https://doi.org/10.1016/j.ajhg.2013.01.001
Apter, A., Laufer, N., Bar-Sever, M., Har-Even, D., Ofek, H., & Weizman, A. (1999). Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients. Biological Psychiatry, 46(4), 532–541. https://doi.org/10.1016/S0006-3223(98)00345-X
Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). The alcohol use disorders identification test, (2nd edn). Geneva: World Health Organization.
Bartoli, F., Crocamo, C., Dakanalis, A., Riboldi, I., Miotto, A., Brosio, E., ... Cerrà, G. (2017). Association between total serum cholesterol and suicide attempts in subjects with major depressive disorder: Exploring the role of clinical and biochemical confounding factors. Clinical Biochemistry, 50(6), 274–278. https://doi.org/10.1016/j.clinbiochem.2016.11.035
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S. et al. (2018). Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation, 137(12), e67–e492.
Bøe-Koholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., ... Kastelein, J. P. (2014). Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials. Journal of the American College of Cardiology, 64(5), 485–494. https://doi.org/10.1016/j.jacc.2014.02.615
Citrome, L. (2007). Comparison of intramuscular ziprasidone, olanzapine, and aripiprazole for agitation: A quantitative review of efficacy and safety. Journal of Clinical Psychiatry, 68(12), 1876–1885. https://doi.org/10.4088/JCP.v68n1207
Coccaro, E. F., Fanning, J. R., Phan, K. L., ... Lee, R. (2015). Serotonin and impulsive aggression. CNS Spectrums, 20(3), 295–302. https://doi.org/10.1017/S1092852915000310
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., ... Peto, R. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 388(10059), 2532–2561. https://doi.org/10.1016/S0140-6736(16)31357-5
De Berardis, D., Campanella, D., Serroni, N., Moschetta, F. S., Di Emidio, F., Conti, C. et al. (2013). Alexithymia, suicide risk and serum lipid levels among adult outpatients with panic disorder. Comprehensive Psychiatry, 54(5), 517–522.
Eriksen, B. M. S., Bjorkly, S., Lockertsen, O., Faerden, A., & Roaldset, J. O. (2017). Low cholesterol level as a risk marker of inpatient and post-discharge violence in acute psychiatry - A prospective study with a focus on gender differences. Psychiatry Research, 255, 1–7.
Fazel, S., Wolf, A., Chang, Z., Larsson, H., Goodwin, G. M., & Lichtenstein, P. (2015). Depression and violence: A Swedish population study. The Lancet Psychiatry, 2(3), 224–232. https://doi.org/10.1016/S2215-0366(14)00128-X
Fazel, S., Wolf, A., Palm, C., & Lichtenstein, P. (2014). Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: A 38-year total population study in Sweden. The Lancet Psychiatry, 1(1), 44–54. https://doi.org/10.1016/S2215-0366(14)00223-8
First, M. B., Spitzer, R., Gibbon, M., & Williams, J. B. W. (1995). Structured clinical interview for DSM-IV axis I disorders, patient edition, version 2. New York, NY: New York State Psychiatric Institute.
Fleischman, A., Werbeloff, N., Yoffe, R., Davidson, M., & Weiser, M. (2014). Schizophrenia and violent crime: A population-based study. Psychological Medicine, 44(14), 3051–3057. https://doi.org/10.1017/S0033291714000695
Freedman, D. S., Byers, T., Barrett, D. H., Stroup, N. E., Eaker, E., & Monroe-Blum, H. (1995). Plasma lipid levels and psychologic characteristics in men. American Journal of Epidemiology, 141(6), 507–517. https://doi.org/10.1093/oxfordjournals.aje.a117465
Hillbrand, M., Spitz, R. T., & Foster, H. G. (1995). Serum cholesterol Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Huang, T., & Wu, S. (2000). Serum cholesterol levels in paranoid and Golomb, B. A., Dimsdale, J. E., Koslik, H. J., Evans, M. A., Lu, X., Rossii, S. M., Dieset, I., Steen, N. E., Morch, R. H., Vedal, T. S. J., Reponen, E. J. ... M., Schuh, L. M., Shao, L., Tohen, M. ... Stauffer, V. L. (2004). An excitement subscale of the Positive and Negative Syndrome Scale. Schizophrenia Research, 68(2–3), 331–337. https://doi.org/10.1016/S0920-9964(03)00087-2 Lindstrom, J. C., Wyller, N. G., Halvorsen, M. M., Hartberg, S., & Lundqvist, C. (2017). Psychometric properties of a Norwegian adaptation of the Barratt Impulsiveness Scale-11 in a sample of Parkinson patients, headache patients, and controls. Brain and Behavior, 7(1), e00605. https://doi.org/10.1002/brb3.605 Lucki, I. (1998). The spectrum of behaviors influenced by serotonin. Biological Psychiatry, 44(3), 151–162. https://doi.org/10.1016/S0006-3223(98)00139-5 Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kvitirovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013). Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA, 310(19), 2061–2068. https://doi.org/10.1001/jama.2013.280532 Mitchell, A. J., Lord, O., & Malone, D. (2012). Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: Meta-analysis. British Journal of Psychiatry, 201(6), 435–443. Montoya, A., Valladares, A., Lizardo, L., San, L., Escobar, R., & Paz, S. (2011). Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health and Quality of Life Outcomes, 9, 18. https://doi.org/10.1186/1477-7525-9-18 Mufli, R. M., Balon, R., & Arfen, C. L. (1998). Low cholesterol and violence. Psychiatric Services (Washington, D. C.), 49(2), 221–224. https://doi.org/10.1176/ps.49.2.221 Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990). Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. BMJ, 301(6747), 309–314. https://doi.org/10.1136/bmj.301.6747.309 Muldoon, M. F., Manuck, S. B., Mendelsohn, A. B., Kaplan, J. R., & Belle, S. H. (2001). Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials. BMJ, 322(7277), 11–15. https://doi.org/10.1136/bmj.322.7277.11 Olfsen, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72(12), 1172–1181. https://doi.org/10.1001/jamapsychiatry.2015.1737 Olsson, A. G., Angelin, B., Assmann, G., Binder, C. J., Bjorkhem, I., Cedazo-Minguez, A., ... Yvan-Charvet, L. (2017). Can LDL cholesterol be too low? Possible risks of extremely low levels. Journal of Internal Medicine, 281(6), 534–553. https://doi.org/10.1111/joim.12614 Osborn, D. P., Hardoon, S., Omar, R. Z., Holt, R. I., King, M., Larsen, J. ... Petersen, I. (2015). Cardiovascular risk prediction models for people with severe mental illness: Results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry, 72(2), 143–151. https://doi.org/10.1001/jamapsychiatry.2014.2133 Paavola, P., Repo-Tiihonen, E., & Tiihonen, J. (2002). Serum lipid levels and violence among Finnish male forensic psychiatric patients. The Journal of Forensic Sciences, 13(3), 555–568. https://doi.org/10.1080/0958518021000019425
Swaraj, S., Stanford, M. S., & Barratt, E. S. (1995). Factor structure of the Barratt Impulsiveness Scale. *Journal of Clinical Psychology, 51*(6), 768-774. https://doi.org/10.1002/1097-4679(199511)51:6<https://doi.org/10.1002/jclp22705160073.0.CO;2-1>

Pearl, J. (2000). *Causality: Models, reasoning and inference* (1st edn). New York, NY: Cambridge University Press.

Pedersen, G., Hagtvet, K. A., & Karterud, S. (2007). Generalizability studies of the Global Assessment of Functioning-Split version. *Comprehensive Psychiatry, 48*(1), 88–94. https://doi.org/10.1016/j.comppsych.2006.03.008

Pietpoli, M. F., Hoes, A. W., Agegwall, S., Albus, C., Brotons, C., Catapano, A. L., ... Verschuren, W. M. M. (2016). 2016 European Guidelines on Cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *European Heart Journal, 37*(29), 2315–2381. https://doi.org/10.1093/eurheartj/ehw106

Reise, S. P., Moore, T. M., Sabb, F. W., Brown, A. K., & London, E. D. (2013). The Barratt Impulsiveness Scale-11: Reassessment of its structure in a community sample. *Psychological Assessment, 25*(2), 631–642. https://doi.org/10.1037/a0032161

Roaldset, J. O., Bakken, A. M., & Bjorkly, S. (2011). A prospective study of lipids and serotonin as risk markers of violence and self-harm in acute psychiatric patients. *Psychiatry Research, 186*(2–3), 293–299.

Rodevand, L., Steen, N. E., Elvisashagen, T., Quintana, D. S., Reponen, E. J., Morch, R. H., Lunding, S. H., Vedal, T. S. J., Dietz, I., Melle, I., Lagerberg, T. V., & Andreassen, O. A. (2019). Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade. *Acta Psychiatrica Scandinavica, 139*(4), 348–360. https://doi.org/10.1111/acps.13008

Rothwell, P. M. (2005). External validity of randomised controlled trials: “to whom do the results of this trial apply?”. *Lancet, 365*(9453), 82–93. https://doi.org/10.1016/S0140-6736(04)67367-8

Sedgwick, O., Young, S., Das, M., & Kumar, V. (2016). Objective predictors of outcome in forensic mental health services—a systematic review. *CNS Spectrums, 21*(6), 430–444. https://doi.org/10.1017/S1092852915000723

Stanford, M. S., Mathias, C. W., Dougherty, D. M., Lake, S. L., Anderson, N. E., & Patton, J. H. (2009). Fifty years of the Barratt Impulsiveness Scale: An update and review. *Personality and Individual Differences, 47*(5), 385–395. https://doi.org/10.1016/j.paid.2009.04.008

Steinert, T., Wellefl, M., & Gebhardt, R. P. (1999). No correlation of serum cholesterol levels with measures of violence in patients with schizophrenia and non-psychotic disorders. *European Psychiatry, 14*(6), 346–348.

Sunesson, K., Asp, M., Traskman-Bendz, L., Westrin, A., Ambrus, L., & Lindqvist, D. (2019). Low total cholesterol and low-density lipoprotein associated with aggression and hostility in recent suicide attempters. *Psychiatry Research, 273*, 430–434.

Swaraj, S., Wang, M., Chung, D., Curtis, J., Firth, J., Ramanuj, P. P., Sara, G., & Large, M. (2019). Meta-analysis of natural and cause-specific mortality rates following discharge from in-patient psychiatric facilities. *Acta Psychiatrica Scandinavica, 140*(3), 244–264. https://doi.org/10.1111/acps.13073

Tanskanen, A., Tihonen, J., & Taipale, H. (2018). Mortality in schizophrenia: 30-year nationwide follow-up study. *Acta Psychiatrica Scandinavica, 138*(6), 492–499. https://doi.org/10.1111/acps.12913

Tomson-Johanson, K., & Harro, J. (2018). Low cholesterol, impulsivity and violence revisited. *Current Opinion in Endocrinology, Diabetes, and Obesity, 25*(2), 103–107. https://doi.org/10.1097/MED.0000000000000395

Tomson-Johanson, K., Kaart, T., Kivi, R. A., Veidebaum, T., & Harro, J. (2019). Low cholesterol levels in children predict impulsivity in young adulthood. *Acta Neuropsychiatria, 1–10*. https://doi.org/10.1017/11.2019.48

Troisi, A. (2011). Low cholesterol is a risk factor for attentional impulsivity in patients with mood symptoms. *Psychiatry Research, 188*(1), 83–87.

Veever, J., Vales, K., Fisar, Z., Hroudová, J., Singh, N., Chuchlik, A., Cačer, P., & Nekovárová, T. (2016). The effect of prolonged simvastatin application on serotonin uptake, membrane microviscosity and behavioral changes in the animal model. *Physiology & Behavior, 158*, 112–120. https://doi.org/10.1016/j.physbeh.2016.02.029

Virkkunen, M. (1979). Serum cholesterol in antisocial personality. *Neuropsychobiology, 5*(1), 27–30. https://doi.org/10.1159/000117660

Voluse, A. C., Gioia, C. J., Sobell, L. C., Dum, M., Sobell, M. B., & Simco, E. R. (2012). Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) with substance abusers in outpatient and residential treatment. *Addictive Behaviors, 37*(1), 36–41. https://doi.org/10.1016/j.addbeh.2011.07.030

Walter, F., Carr, M. J., Mok, P. L. H., Antonsen, S., Pedersen, C. B., Appleby, L. et al. (2019). Multiple adverse outcomes following first discharge from inpatient psychiatric care: A national cohort study. *The Lancet Psychiatry, 6*(7), 582–589. https://doi.org/10.1016/S2215-0366(19)30180-4

White, L., Harvey, P. D., Opler, L., & Lindenmayer, J. P. (1997). Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. *Psychopathology, 30*(5), 263–274. https://doi.org/10.1159/000285058

Woodhead, C., Ashworth, M., Broadbent, M., Callard, F., Hotopf, M., Schofield, P., ... Henderson, M. J. (2016). Cardiovascular disease treatment among patients with severe mental illness: A data linkage study between primary and secondary care. *British Journal of General Practice, 66*(647), e374–e381. https://doi.org/10.3399/bjgp16X685189

Wu, S., Ding, Y., Wu, F., Xie, G., Hou, J., & Mao, P. (2016). Serum lipid levels and suicidality: A meta-analysis of 65 epidemiological studies. *Journal of Psychiatry and Neuroscience, 41*(1), 56–69.

Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978). A rating scale for mania: Reliability, validity and sensitivity. *British Journal of Psychiatry, 133*, 429–435. https://doi.org/10.1192/bjp.133.5.429

Zeller, S., Zun, L., Cassella, J. V., Spyker, D. A., & Yeung, P. P. (2017). Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. *BJPsych Open, 3*(6), 285–290. https://doi.org/10.1192/bjpo.bp.117.005363.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Hjell G, March-Johnsen L, Holst R, et al. Disentangling the relationship between cholesterol, aggression, and impulsivity in severe mental disorders. *Brain Behav.* 2020;10:e01751. https://doi.org/10.1002/brb3.1751